Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals Inc (NQ: APLS )

41.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 21
Open 41.95
Bid (Size) 4.400 (1)
Ask (Size) 60.00 (1)
Prev. Close 41.95
Today's Range 41.95 - 41.95
52wk Range 27.50 - 73.00
Shares Outstanding 106,521,818
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Apellis Pharmaceuticals
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3%... 
Via Benzinga

Performance

YTD
-13.98%
-13.98%
1 Month
-9.67%
-9.67%
3 Month
-3.18%
-3.18%
6 Month
-3.65%
-3.65%
1 Year
-18.83%
-18.83%

More News

Read More
Expert Ratings for Apellis Pharmaceuticals
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies
Via Benzinga
Earnings Scheduled For February 28, 2022
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
Apellis Pharmaceuticals's Earnings: A Preview
Via Benzinga
Expert Ratings for Apellis Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Via Benzinga
Apellis Pharmaceuticals Stock Shows Rising Relative Strength
Via Investor's Business Daily
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Apellis Pharmaceuticals Stock Is Falling After Hours
Via Benzinga
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing
Via Investor's Business Daily
Here's Why Apellis Pharmaceuticals Shares Are Rising
Via Benzinga
The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study
Via Benzinga
Expert Ratings For Apellis Pharmaceuticals
Via Benzinga
Where Apellis Pharmaceuticals Stands With Analysts
Via Benzinga
Apellis Pharmaceuticals: Q4 Earnings Insights
Via Benzinga
Apellis Pharmaceuticals's Earnings Outlook
Via Benzinga
Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder
Via Benzinga
The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO
Via Benzinga
What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.